NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CELC

Celcuity Inc

Jul 11 • 04:00PM ET

13.63

Dollar change +0.01
Percentage change 0.07	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD ACAD NBIX BIIB BMRN EXEL ALKS INCY BHVN IONS

| Held by: VTI IWM VXF IWO SCHA VTWO IDNA IWC ITOT VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.03	Insider Own	18.54%	Shs Outstand	37.84M	Perf Week	-1.16%
Market Cap	516.12M	Forward P/E	-	EPS next Y	-3.29	Insider Trans	0.00%	Shs Float	30.85M	Perf Month	5.50%
Enterprise Value	409.14M	PEG	-	EPS next Q	-0.88	Inst Own	76.57%	Short Float	7.82%	Perf Quarter	57.57%
Income	-127.16M	P/S	-	EPS this Y	-19.04%	Inst Trans	2.97%	Short Ratio	13.14	Perf Half Y	2.56%
Sales	0.00M	P/B	5.95	EPS next Y	2.25%	ROA	-62.59%	Short Interest	2.41M	Perf YTD	4.13%
Book/sh	2.29	P/C	2.51	EPS next 5Y	31.69%	ROE	-115.39%	52W High	19.77 -31.06%	Perf Year	-20.39%
Cash/sh	5.43	P/FCF	-	EPS past 3/5Y	-8.60% -31.53%	ROIC	-68.66%	52W Low	7.57 79.93%	Perf 3Y	45.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.42% 5.71%	Perf 5Y	96.12%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-8.45%	Oper. Margin	-	ATR (14)	0.72	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.61	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	62.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.61	EPS Q/Q	-33.64%	SMA20	7.96%	Beta	0.54	Target Price	28.71
Payout	-	Debt/Eq	1.14	Sales Q/Q	-	SMA50	16.50%	Rel Volume	0.93	Prev Close	13.62
Employees	87	LT Debt/Eq	1.14	Earnings	May 14 AMC	SMA200	11.27%	Avg Volume	183.68K	Price	13.63
IPO	Sep 20, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.20% -	Trades		Volume	171,535	Change	0.07%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-25	Resumed	Stifel	Buy	$30
Jul-22-24	Initiated	Leerink Partners	Outperform	$29
Feb-22-24	Initiated	Stifel	Buy	$40
Dec-08-23	Initiated	H.C. Wainwright	Buy	$27
Oct-08-21	Initiated	Canaccord Genuity	Buy	$50
Sep-07-21	Initiated	Jefferies	Buy	$48
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy	$50
Jan-28-21	Reiterated	H.C. Wainwright	Buy	$14 → $18
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$11 → $14
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy	$36

Show Previous Ratings

Jun-30-25 07:05AM	Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib (GlobeNewswire) +6.46%
May-21-25 07:05AM	Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences (GlobeNewswire)
May-15-25 09:56AM	Q1 2025 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Celcuity Inc (CELC) Q1 2025 Earnings Call Highlights: Navigating Increased Losses and Strategic ... (GuruFocus.com)
May-14-25 04:01PM	Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
07:05AM	Loading…
May-07-25 07:05AM	Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Apr-01-25 08:41AM	Q4 2024 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) -8.11%
07:05AM	Celcuity To Present at Upcoming Needham and Stifel Investor Conferences (GlobeNewswire)
03:03AM	Celcuity Inc (CELC) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... (GuruFocus.com)
Mar-31-25 10:50PM	Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:01PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-25 07:05AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-25-25 07:05AM	Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences (GlobeNewswire) -8.99%
Dec-11-24 07:05AM	Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
02:20AM	Loading…
Nov-15-24 02:20AM	Celcuity Inc (CELC) Q3 2024 Earnings Call Highlights: Clinical Milestones and Financial Challenges (GuruFocus.com) -10.28%
Nov-14-24 04:01PM	Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-12-24 07:05AM	Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences (GlobeNewswire)
Nov-07-24 07:05AM	Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Oct-09-24 06:26PM	Celcuity Inc (CELC) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses (GuruFocus.com) -5.83%
Oct-07-24 09:10PM	Morgan Stanley's Strategic Reduction in Celcuity Inc Holdings (GuruFocus.com)
Sep-10-24 09:55AM	Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-20-24 12:00PM	Celcuity (CELC) Upgraded to Buy: Here's Why (Zacks)
Aug-14-24 04:01PM	Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 07:05AM	Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jun-03-24 04:01PM	Celcuity To Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -5.25%
May-30-24 07:36AM	Celcuity Announces Pricing of Underwritten Common Stock Offering (GlobeNewswire)
07:00AM	Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing (GlobeNewswire)
May-16-24 11:54AM	Craig-Hallum Adjusts Price Target on Celcuity to $27 From $25, Assumes Buy Rating (MT Newswires)
03:08AM	Celcuity Inc (CELC) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ... (GuruFocus.com)
08:55PM	Loading…
May-15-24 08:55PM	CELC Stock Earnings: Celcuity Beats EPS for Q1 2024 (InvestorPlace)
06:04PM	Celcuity Q1 Net Loss Widens; Shares Rise After Hours (MT Newswires)
04:01PM	Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 07:05AM	Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire)
Apr-04-24 07:05AM	Celcuity To Present at Upcoming Needham and Stifel Investor Conferences (GlobeNewswire)
Apr-01-24 01:38PM	Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 06:51AM	Q4 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) +18.94%
Mar-27-24 08:53PM	CELC Stock Earnings: Celcuity Beats EPS for Q4 2023 (InvestorPlace)
05:51PM	Celcuity Inc (CELC) Reports Full Year 2023 Financial Results and Highlights Key Developments (GuruFocus.com)
04:01PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-21-24 11:17AM	Why Celcuity (CELC) Might Surprise This Earnings Season (Zacks)
Mar-20-24 07:05AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Mar-06-24 07:05AM	Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-28-24 07:05AM	Celcuity to Participate in Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-22-24 04:05PM	Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Feb-20-24 07:05AM	Celcuity Appoints Eldon Mayer as Chief Commercial Officer (GlobeNewswire) -5.51%
Dec-06-23 08:30AM	Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-01-23 11:02AM	Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-22-23 08:05AM	Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-23 10:50AM	Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call Transcript (Insider Monkey) +10.10%
Nov-13-23 09:41PM	Q3 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
10:54AM	Celcuity Inc (CELC) Reports Q3 2023 Financial Results and Strategic Developments (GuruFocus.com)
07:05AM	Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-06-23 07:30AM	Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Nov-01-23 07:05AM	Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences (GlobeNewswire) -5.35%
Oct-18-23 09:15AM	Celcuity Inc. Announces $50 Million Private Placement (ACCESSWIRE) +11.38%
Sep-21-23 04:43PM	The 7 Best Short-Squeeze Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-07-23 04:05PM	Celcuity to Host Virtual Science Day for Investors (GlobeNewswire)
Sep-06-23 07:10PM	7 Short-Squeeze Stocks That Actually Might Make Sense (InvestorPlace)
Aug-22-23 04:05PM	Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial (GlobeNewswire)
04:01PM	Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Aug-11-23 05:58AM	Q2 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:04PM	Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-03-23 07:30AM	Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jul-31-23 08:00AM	Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-27-23 06:51AM	Celcuity Inc. (NASDAQ:CELC) stock most popular amongst individual investors who own 23%, while private equity firms hold 22% (Simply Wall St.)
Jun-20-23 09:02AM	Celcuity Set to Join Russell 2000 and 3000 Indexes (ACCESSWIRE)
May-24-23 08:00AM	Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences (ACCESSWIRE)
07:59AM	Insiders of Celcuity Getting Good Value On Their US$1.6m Investment \ (Simply Wall St.)
May-16-23 06:26AM	Q1 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-23 04:00PM	Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates (ACCESSWIRE)
May-12-23 06:15AM	Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress (ACCESSWIRE)
May-08-23 05:30PM	Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call (ACCESSWIRE)
08:00AM	Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress (ACCESSWIRE)
Apr-18-23 01:30PM	Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 (ACCESSWIRE)
Apr-12-23 08:00AM	Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference (ACCESSWIRE)
Mar-27-23 02:43AM	Celcuity Inc. (NASDAQ:CELC) Q4 2022 Earnings Call Transcript (Insider Monkey) +13.56%
Mar-24-23 07:07AM	Q4 2022 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) -5.47%
Mar-23-23 04:00PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Mar-16-23 08:00AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call (ACCESSWIRE)
Mar-15-23 07:35PM	Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023 (ACCESSWIRE)
Mar-01-23 08:00AM	Celcuity to Participate in Cowen's 43rd Annual Health Care Conference (ACCESSWIRE)
Feb-17-23 05:07AM	While institutions own 25% of Celcuity Inc. (NASDAQ:CELC), individual investors are its largest shareholders with 58% ownership (Simply Wall St.)
Feb-16-23 08:00AM	Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium (ACCESSWIRE)
Dec-18-22 04:38AM	Insiders pour millions into these 3 stocks this is what makes them attractive buys (TipRanks)
Dec-15-22 05:59AM	Bullish insiders bet US$1.6m on Celcuity Inc. (NASDAQ:CELC) (Simply Wall St.)
Dec-12-22 07:30AM	Celcuity Closes $100 Million Private Placement (ACCESSWIRE) +11.62%
Dec-09-22 08:40AM	Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium (ACCESSWIRE)
Dec-07-22 04:00PM	Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer (ACCESSWIRE) -6.21% +26.36%
Nov-22-22 07:30AM	Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium (ACCESSWIRE) -5.36%
Nov-10-22 04:30PM	Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference (ACCESSWIRE)
04:00PM	Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-03-22 08:50AM	Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call (ACCESSWIRE)
Sep-14-22 09:00AM	Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors (ACCESSWIRE)
Aug-15-22 09:39AM	What Is The Ownership Structure Like For Celcuity Inc. (NASDAQ:CELC)? (Simply Wall St.)
Aug-11-22 04:00PM	Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-04-22 08:15AM	Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call (ACCESSWIRE) +5.66%
Aug-03-22 10:15AM	Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference (ACCESSWIRE) +10.74%
Jul-18-22 06:31PM	Celcuity stock soars after hours on breakthrough therapy designation for cancer drug (MarketWatch)

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Furcht Leo	Director	Dec 02 '24	Option Exercise	3.60	250	900	10,750	Dec 03 06:11 PM
Buller Richard E	Director	Oct 23 '24	Sale	16.25	350	5,688	6,681	Oct 25 04:15 PM
Buller Richard E	Director	Aug 23 '24	Sale	16.95	350	5,932	7,031	Aug 27 04:13 PM
Buller Richard E	Director	Aug 23 '24	Proposed Sale	16.95	700	11,865		Aug 23 10:27 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CELC

Celcuity Inc

Upgrade your FINVIZ experience